DCC3967 |
P505-15 Acetate |
Selective spleen tyrosine kinase (SYK) inhibitor, suppressing leukocyte immune function and inflammation, and leading to a reduction in arthritis score and attenuated histological damage |
|
DCC3968 |
p53 Modulator 10d |
Novel modulator of p53 activity, arresting at G2/M phase inducing delay of cell cycle progression |
|
DCC3969 |
P53 Reactivator C85 |
Novel reactivator of mutant p53, fuctioning as a zinc metallochaperone (ZMC) with diminished copper binding that functions as a chemotherapy and radiation sensitizer |
|
DCC3970 |
P5-peptide |
Novel inhibitor of atherogenesis and diabetes, significantly and specifically inhibiting αD-CEP binding |
|
DCC3971 |
P7 Peptide |
Novel bFGF antagonist peptide, inhibiting breast cancer cell growth |
|
DCC3972 |
P7c3a20 |
Neuroprotective agent, protecting ventral horn spinal cord motor neurons from cell death |
|
DCC3973 |
P97-in-17 |
Novel potent inhibitor of the AAA+ ATPase p97 |
|
DCC3974 |
P97-in-23 |
Novel potent inhibitor of the AAA+ ATPase p97 |
|
DCC3975 |
Pa Autoinducer |
Pseudomonas aeruginosa autoinducer |
|
DCC3976 |
Pa-082 |
Novel partial agonist of peroxisome proliferator-activated receptor-γ (PPARγ), recruiting PPARγ-coactivator-1α, preventing triglyceride accumulation, and potentiating insulin signaling in vitro |
|
DCC3977 |
Pa1 Dihydrochloride |
Photoswitchable epithelial sodium channel (ENaC) blocker |
|
DCC3978 |
Paba/no |
Novel glutathione-S-transferase-p-activated nitric oxide donor, inhibiting proliferation and inducing apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells |
|
DCC3979 |
Pad3-in-14b |
Novel potent and selective inhibitor of protein arginine deiminase 3 (PAD3), having 15600 kinact/KI values and ≥10-fold selectivity for PAD3 over PADs 1, 2, and 4. |
|
DCC3980 |
pal-1045 |
Partial DAT/5-HT transporter substrate |
|
DCC3981 |
pal-1046 |
Full DAT/5-HT transporter substrate |
|
DCC3982 |
Pal-12 |
Novel selective LYPLAL1 activator, increasing LYPLAL1’s catalytic activity likely by enhancing the efficiency of the catalytic triad charge-relay system, confering beneficial effects in a mouse model of diet-induced obesity |
|
DCC3983 |
pal-287 |
Full DAT/5-HT transporter substrate; Non-neurotoxic releasing agent of serotonin, norepinephrine, and dopamine; Full agonist at 5-HT2B and partial agonist at 5-HT2C |
|
DCC3984 |
Pal-545 Hydrochloride |
Potent dual dopamine-serotonin (DA/5-HT) releaser |
|
DCC3985 |
Palbociclib Dihydrochloride
Featured
|
Selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6 |
|
DCC3986 |
Palmostatin M |
Novel Ras-Signaling Modulator, targeting acyl protein thioesterase 1 (APT1) and 2 (APT2) in cells |
|
DCC3987 |
Palonosetron |
Potent serotonin-3 (5-HT3) receptor antagonist |
|
DCC3988 |
Pam2cys |
Novel TLR2 agonist as potential adjuvant for cancer vaccines |
|
DCC3989 |
Pancratistatin |
Inhibitor of the Cell_cycle>cell cycle from G0/G1 to S phase with powerful antiparasite activity |
|
DCC3990 |
Panduratin A |
Biological Active Reagents |
|
DCC3991 |
panomifene |
Tamoxifen analogue; antiestrogenic |
|
DCC3992 |
Pan-raf/rtk Inhibitor I-16 |
Novel potent pan-Raf and receptor tyrosine kinase inhibitor, potently inhibits all subtypes of Rafs with IC50 values of 3.49 (BRafV600E), 8.86 (ARaf), 5.78 (BRafWT), and 1.65 nM (CRaf), respectively |
|
DCC3993 |
Pao-pdt |
Potent and highly selective small molecule inhibitor of thioredoxin reductase (TrxR) |
|
DCC3994 |
Pape-1 |
Pathway Preferential Estrogen, activating the extranuclear signaling pathway without activity on the nuclear signaling pathway |
|
DCC3996 |
Para-aminoblebbistatin |
Blebbistatin derivative, increasing water solubility, decreases the inherent fluorescence, stabilizing the molecule to circumvent its degradation by prolonged blue light exposure, and decreasing its phototoxicity while retaining the in vitro and in vivo a |
|
DCC3997 |
Para-cid-5951923 |
Isomer of CID-5951923 |
|